E3 ubiquitin ligase NKLAM/RNF19b suppresses myc-driven B cell lymphomagenesis in Eμ-myc mice
Frontiers in Oncology · 15.07.2026 · 16
DOI: 10.3389/fonc.2026.1874366 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 15.07.2026. Verfasst von Richard G Hoover und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Saint Louis University School of Medicine, St. Louis, MO, United States. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, U.S. Department of Veterans Affairs.
Abstract (Originalsprache)
Introduction
Natural Killer Lytic-Associated Molecule (NKLAM) (also known as RNF19b) is a membrane-bound E3 ubiquitin ligase. Previous studies demonstrated a role of NKLAM in natural killer (NK) cell function and pro-inflammatory cytokine production by macrophages. Studies using lymphoma, melanoma and breast cancer cells found that tumor dissemination and metastasis are greater in NKLAM-deficient knockout (KO) mice than in wild type (WT) mice, indicating that NKLAM participates in controlling tumor development in vivo .
Methods
We employed the Eμ-myc mouse model to determine whether NKLAM influences B cell lymphomagenesis. In young Eμ-myc mice, overexpression of myc in B lineage cells leads to expansion of non-neoplastic precursor B cells, which subsequently disappear. Over time, pre-B, pro-B or immature B cell lymphomas develop.
Results
NKLAM KO Eμ-myc mice have higher levels of precursor B cells than WT transgenic mice. These cells express more myc and Bcl-2 and persist longer. Lymphomas develop more rapidly in NKLAM KO Eμ-myc mice and strikingly, have a more differentiated phenotype, characterized by surface IgM. These lymphomas are also less aggressive than IgM- tumors when injected into non-transgenic mice. Infusion of NKLAM+ immune cells into young NKLAM KO Eμ-myc mice extends their survival, which increases the proportion of mice that develop more aggressive, immune-resistant IgM- lymphomas.
Discussion
These studies indicate that NKLAM contributes to both the early and late phases of myc-driven B cell lymphomagenesis, first by limiting expression of myc and Bcl-2 within the non-malignant pre-B cells, resulting in longer tumor-free survival. This is followed by immunoediting by NKLAM+ immune cells, leading to development of IgM- lymphomas that are less immunogenic and more aggressive.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Saint Louis University School of Medicine, St. Louis, MO, United States.
- Research and Development Service, St. Louis VA Medical Center, St. Louis, MO, United States.
Förderung
- BLRD VA
- U.S. Department of Veterans Affairs
Zitieren
APA
Hoover, R. G., Matchett, E. C., & Kornbluth, J. (2026). E3 ubiquitin ligase NKLAM/RNF19b suppresses myc-driven B cell lymphomagenesis in Eμ-myc mice. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1874366
Vancouver
Hoover RG, Matchett EC, Kornbluth J. E3 ubiquitin ligase NKLAM/RNF19b suppresses myc-driven B cell lymphomagenesis in Eμ-myc mice. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1874366
BibTeX
@article{Hoover2026,
author = {Hoover, Richard G and Matchett, Emily C and Kornbluth, Jacki},
title = {E3 ubiquitin ligase NKLAM/RNF19b suppresses myc-driven B cell lymphomagenesis in Eμ-myc mice},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1874366}
}
EUVIMED